Open AccessActivation of Cannabinoid Receptor Type II by AM1241 Ameliorates Myocardial Fibrosis via Nrf2-Mediated Inhibition of TGF-β1/Smad3 Pathway in Myocardial Infarction Mice
Author(s) -
Xiang Li,
Dongyi Han,
Zuhong Tian,
Beilei Gao,
Min Fan,
Congye Li,
Xiujuan Li,
Yabin Wang,
Sai Ma,
Feng Cao
Publication year - 2016
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000447855
Subject(s) - sirius red , myocardial fibrosis , fibrosis , medicine , receptor , fibronectin , cannabinoid receptor type 2 , cardiac fibrosis , myocardial infarction , western blot , agonist , endocrinology , pharmacology , chemistry , cannabinoid receptor , cell , biochemistry , gene
Myocardial interstitial fibrosis is a major histologic landmark resulting in cardiac dysfunction after myocardial infarction (MI). Activation of cannabinoid receptor type II (CB2 receptor) have been demonstrated to reduce fibrosis in hepatic cirrhotic rat. However, the anti-fibrotic effect of CB2 receptor activation in infarcted hearts was still unclear. In this study, we aimed to investigate the effects of a CB2 receptor selective agonist AM1241 on myocardial fibrosis post MI in mice.